Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. Show more

Location: 900 Chesapeake Drive, Redwood City, CA, 94063, United States | Website: https://www.boltbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

9.286M

52 Wk Range

$4.59 - $14.36

Previous Close

$4.84

Open

$4.93

Volume

2,937

Day Range

$4.84 - $4.95

Enterprise Value

-1.30M

Cash

34.77M

Avg Qtr Burn

-12.84M

Insider Ownership

2.26%

Institutional Own.

44.74%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.